Compare BSP & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSP | GMAB |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | Italy | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8B | 20.3B |
| IPO Year | 2023 | 2008 |
| Metric | BSP | GMAB |
|---|---|---|
| Price | $32.75 | $34.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $47.67 | $39.14 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $121.36 | $23.39 |
| Revenue Next Year | $45.56 | $16.04 |
| P/E Ratio | ★ N/A | $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.11 | $23.62 |
| 52 Week High | $58.94 | $35.79 |
| Indicator | BSP | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 67.85 |
| Support Level | $31.06 | $32.38 |
| Resistance Level | $36.13 | N/A |
| Average True Range (ATR) | 2.25 | 0.75 |
| MACD | -0.55 | 0.03 |
| Stochastic Oscillator | 12.54 | 94.62 |
Bending Spoons SpA acquires and operates digital businesses, focusing on business transformation and operational optimization. Its activities include acquiring companies, implementing operational improvements, and reinvesting in additional acquisitions. The company owns AOL, Brightcove, Eventbrite, Evernote, Harvest, Komoot, Meetup, Remini, StreamYard, Vimeo, and WeTransfer. The majority of revenue is derived from subscriptions, by selling term-based access to its products to individuals and organizations, and the rest from advertising and other sources.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.